Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Press release

Ultralife Corporation Reports Second Quarter Results

ex_1001163img001.jpg

NEWARK, N.Y. – August 7, 2026 -- Ultralife Corporation (NASDAQ: ULBI) reported operating results for the second quarter ended June 30, 2026 with the following results:

  • Sales of $47.9 million compared to $48.6 million for the 2025 second quarter

  • Gross profit of $13.9 million, or 28.9% of revenue, compared to $11.6 million, or 23.9% of revenue, for the 2025 second quarter; excluding a $1.1 million net IEEPA refund received in the 2026 second quarter, gross margin was 26.6%

  • Operating income of $3.4 million, including one-time costs of $0.9 million, compared to $2.3 million including one-time costs of $0.3 million for the 2025 second quarter

  • GAAP EPS of $0.15 compared to $0.05 for the 2025 second quarter

  • Adjusted EBITDA of $6.1 million compared to $4.1 million for the 2025 second quarter

  • Backlog of $117.5 million compared to $115.1 million exiting the first quarter of 2026

“For the second quarter we delivered a 760-basis point improvement in gross profit margin compared to the first quarter, including the contribution of the net IEEPA refund. This improvement reflects measurable benefits realized to date from our initiatives to address manufacturing inefficiencies along with favorable sales mix. Our Communications Systems business is poised to produce revenue gains as new products move through the capture phase, and continues to expand its opportunity funnel while preparing to launch multiple new products later this year in support of government/defense programs. At the same time, we are advancing a diverse set of product development programs in our Battery & Energy Products business including programs to support water-based defense drone applications. Several of these programs are expected to transition into production later this year while we continue to execute our backlog. These multi-year revenue opportunities combined with our ongoing gross margin improvement initiatives, reinforce our outlook for profitable growth in 2026,” said Mike Manna, President and Chief Executive Officer.

Second Quarter 2026 Financial Results

Revenue was $47.9 million, a decrease of $0.6 million, or 1.3%, as compared to revenue of $48.6 million for the second quarter of 2025. Battery & Energy Products sales decreased 3.7% to $44.2 million compared to $45.9 million last year. The year-over-year decrease reflects a 4.7% decline in commercial sales due to an 8.7% decline in oil & gas and industrial sales offsetting a 7.2% increase in medical battery sales, and a 1.4% decline in government/defense sales due to the shipment of a very large order for an allied country last year. Communications Systems sales increased by 39.3% to $3.8 million compared to $2.7 million for the same period last year. Our total backlog exiting the second quarter was $117.5 million, the highest level in the Company’s history, compared to $115.1 million exiting the first quarter of 2026 and $84.5 million exiting the second quarter of 2025.

Gross profit was $13.9 million, or 28.9% of revenue, compared to $11.6 million, or 23.9% of revenue, for the same quarter a year ago. Battery & Energy Products gross margin was 28.3%, compared to 23.6% last year, primarily due to favorable product mix and the refund of the IEEPA tariffs in the current period. Communications Systems gross margin was 36.3% compared to 28.4% last year, primarily due to sales mix.

Operating expenses were $10.4 million, compared to $9.3 million for the second quarter of 2025, reflecting an increase in new product development costs related to continued investment in our product offering, and one-time, non-recurring costs of $0.9 million primarily related to litigation expenses incurred for our cyber-insurance claim and the completion of certain consulting costs to help expedite our gross margin improvement. Operating expenses were 21.8% of revenue compared to 19.2% of revenue for the year-earlier period.

Operating income was $3.4 million compared to $2.3 million last year.

Other expense was $0.5 million primarily comprised of interest expense from the financing of our Electrochem acquisition partially offset by the second quarter estimated portion of a refundable tax credit for certain qualifying battery cells and packs we manufacture under the 45X Advanced Manufacturing Production Tax Credit. This compares to $1.1 million for the year-earlier period primarily reflecting the Electrochem acquisition financing and net foreign currency losses.

Net income attributable to Ultralife Corporation was $2.5 million or $0.15 per basic and diluted share on a GAAP basis, compared to $0.9 million or $0.05 per basic and diluted share for the second quarter of 2025.

Adjusted EBITDA, defined as EBITDA including non-cash, stock-based compensation expense and one-time costs not reflective of our ongoing operations, was $6.1 million for the second quarter of 2026, or 12.8% of sales, compared to $4.1 million, or 8.5% of sales, for the year-earlier period. On a trailing twelve-month basis, adjusted EBITDA was $17.1 million or 9.1% of sales.

See the “Non-GAAP Financial Measures” section of this release for a reconciliation of adjusted EBITDA to net income attributable to Ultralife Corporation.

About Ultralife Corporation

Ultralife Corporation serves its markets with products and services ranging from power solutions to communications and electronics systems. Through its engineering and collaborative approach to problem solving, Ultralife serves government/defense and commercial customers across the globe.

Headquartered in Newark, New York, the Company's business segments include Battery & Energy Products and Communications Systems. Ultralife has operations in North America, Europe and Asia. For more information, visit www.ultralifecorporation.com.

Conference Call Information

Ultralife will hold its second quarter earnings conference call today at 8:00 AM ET.

To ensure a fast and reliable connection to our investor conference call, we now require participants dialing in by phone to register using the following link prior to the call: https://register-conf.media-server.com/register/BI4beea58f157a441ba44284b283b1001f. This will eliminate the need to speak with an operator. Once registered, dial-in information will be provided along with a personal identification number. Should you register early and misplace your details, you can simply click back on this same link at any time to register and view this information again. A live webcast of the conference call will be available to investors in the Events & Presentations section of the Company's website at http://investor.ultralifecorporation.com. For those who cannot listen to the live broadcast, a replay of the webcast will be available shortly after the call at the same location.

This press release may contain forward-looking statements based on current expectations that involve a number of risks and uncertainties. The potential risks and uncertainties that could cause actual results to differ materially include uncertain global economic conditions including the impact of tariffs and inflation, reductions in revenues from key customers, delays or reductions in U.S. and foreign military spending, acceptance of our new products on a global basis, and disruptions, delays or material price increases in our supply of raw materials and components due to business conditions, new or additional tariffs, global conflicts, weather or other factors not under our control. The Company cautions investors not to place undue reliance on forward-looking statements, which reflect the Company's analysis only as of today's date. The Company undertakes no obligation to publicly update forward-looking statements to reflect subsequent events or circumstances. Further information on these factors and other factors that could affect Ultralife’s financial results is included in Ultralife’s Securities and Exchange Commission (SEC) filings, including the latest Annual Report on Form 10-K.

ULTRALIFE CORPORATION AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS (Dollars in Thousands)

(Unaudited)

June 30, 

2026

December 31, 2025

ASSETS

Current Assets:

Cash

$6,663

$9,345

Trade Accounts Receivable, Net

34,770

33,948

Inventories, Net

58,745

54,008

Prepaid Expenses and Other Current Assets

6,980

8,500

Total Current Assets

107,158

105,801

Property, Plant and Equipment, Net

39,514

40,397

Goodwill

45,369

45,376

Other Intangible Assets, Net

10,386

10,933

Deferred Income Taxes, Net

10,335

10,494

Other Non-Current Assets

3,395

3,911

​Total Assets

$216,157

$216,912

LIABILITIES AND SHAREHOLDERS' EQUITY

​Current Liabilities:

Accounts Payable

$22,601

$17,423

Current Portion of Long-Term Debt

1,750

4,125

Accrued Compensation and Related Benefits

2,930

2,754

Accrued Expenses and Other Current Liabilities

10,074

13,031

Total Current Liabilities

37,355

37,333

Long-Term Debt, Net

42,854

45,526

Deferred Income Taxes, Net

1,000

Other Non-Current Liabilities

2,413

2,919

Total Liabilities

83,556

86,778

Shareholders' Equity:

Common Stock

2,110

2,109

Capital in Excess of Par Value

192,983

192,859

Accumulated Deficit

(38,248)

(40,340)

Accumulated Other Comprehensive Loss

(2,846)

(3,141)

Treasury Stock

(21,492)

(21,492)

Total Ultralife Equity

132,507

129,995

Non-Controlling Interest

Total Shareholders’ Equity

132,601

130,134

Total Liabilities and Shareholders' Equity

$216,157

$216,912

ULTRALIFE CORPORATION AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF INCOME

(In Thousands Except Per Share Amounts)

(Unaudited)

Three-Month Period Ended

Six-Month Period Ended

June 30,

June 30,

June 30,

June 30,

2026

2025

2026

2025

Revenues:

Battery & Energy Products

$44,189

$45,867

$88,344

$92,188

Communications Systems

3,754

2,694

7,044

7,119

Total Revenues

47,943

48,561

95,388

99,307

Cost of Products Sold:

Battery & Energy Products

31,686

35,032

66,483

69,913

Communications Systems

2,391

1,928

4,929

5,048

Total Cost of Products Sold

34,077

36,960

71,412

74,961

Gross Profit

13,866

11,601

23,976

24,346

Operating Expenses:

Research and Development

3,225

2,318

6,186

4,722

Selling, General and Administrative

7,204

7,027

14,568

13,969

Total Operating Expenses

10,429

9,345

20,754

18,691

Operating Income

3,437

2,256

3,222

5,655

Other Expense

1,143

2,096

Income Before Income Taxes

2,986

1,113

2,323

3,559

Income Tax Provision

Net Income

2,518

2,047

2,749

Net (Loss) Income Attributable to Non-Controlling Interest

(25)

(9)

(45)

Net Income Attributable to Ultralife Corporation

$2,543

$879

$2,092

$2,744

Net Income Per Share Attributable to Ultralife Common Shareholders – Basic

$.15

$.05

$.13

$.17

Net Income Per Share Attributable to Ultralife Common Shareholders – Diluted

$.15

$.05

$.13

$.17

Weighted Average Shares Outstanding – Basic

16,659

16,635

16,658

16,634

Weighted Average Shares Outstanding – Diluted

16,714

16,656

16,703

16,671

Non-GAAP Financial Measures

Adjusted EBITDA

In evaluating our business, we consider and use adjusted EBITDA, a non-GAAP financial measure, as a supplemental measure of our operating performance in addition to GAAP financial measures. We define adjusted EBITDA as net income attributable to Ultralife Corporation before net interest expense, provision for income taxes, depreciation and amortization, and stock-based compensation expense, plus/minus expense/income that we do not consider reflective of our ongoing continuing operations. We reconcile adjusted EBITDA to net income attributable to Ultralife Corporation, the most comparable financial measure under GAAP. Neither current nor potential investors in our securities should rely on adjusted EBITDA as a substitute for any GAAP measures and we encourage investors to review the following reconciliation of adjusted EBITDA to net income attributable to Ultralife Corporation.

ULTRALIFE CORPORATION AND SUBSIDIARIES

CALCULATION OF ADJUSTED EBITDA

(Dollars in Thousands)

(Unaudited)

Three-Month Period Ended

Six-Month Period Ended

June 30, 2026

June 30, 2025

June 30, 2026

June 30, 2025

Net Income Attributable to Ultralife Corporation

$2,543

$879

$2,092

$2,744

Adjustments:

Interest Expense, Net

1,707

2,024

Income Tax Provision

Depreciation Expense

1,056

1,008

2,110

1,958

Amortization Expense

Stock-Based Compensation Expense

Other Non-Recurring Costs

1,731

One-Time Events Impacting Production

-

-

-

Severance Cost for Plant Closure

-

-

-

Non-Cash Purchase Accounting Adjustment

-

-

Adjusted EBITDA

$6,148

$4,113

$9,357

$9,561

Company Contact:

Ultralife Corporation

Philip A. Fain

(315) 210-6110

pfain@ulbi.com

Investor Relations Contact:

Alliance Advisors IR

Jody Burfening

(212) 838-3777

jburfening@allianceadvisors.com

Source: Ultralife Corporation. This release was filed with the U.S. Securities and Exchange Commission on Aug 7, 2026 and is reproduced here as issued. View the filing.

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.